Abstract:OBJECTIVE:To investigate the incidence and clinicopathologic significance of MSI and LOH on 3P in breast carcinoma and its precancerous lesions, intraductal papillary adenoma and ductal carcinoma in situ.METHODS:41 paired sporadic invasive breast carcinomas, 13 archival precancerous lesion specimens of the breast and 14 couples of benign hyperplasia were collected. Twelve microsatellites on chromosomes 2p, 3p, 5q, 6q, 16q, 17q, eleven markers on chromosome 3p were amplified for MSI and LOH, respectively, by polymerase chain reaction ( PCR ) with designed primers and detecting after polyacrylamide gel electrophoresis. In addition, the expression of protein of hMSH2, hMLHI, FHIT, ER, and PR were detected by immunohistochemistry.RESULTS:MSI was observed, at least two microsatellite markers, in 15 out of 41 (36. 6%) of the carcinomas, almost all belonging to poorly or intermediately differentiated carcinoma. Instability was shown in 9 of the 13 cases of precancerous lesions, but only 2 among them had more than 2 MSI sites. There was no MSI in benign hyperplasia. MSI was targeted predominately at D3S1766, D2S2739 in both carcinomas and precancerous lesions. Of the 11 loci examined, D3S1295, D3S1029 and D3S1038 were identified as the locus with most frequent LOH which were all correlated significantly with some clinicopathological parameters such as histological type, lymph node metastasis in breast cancer, while D3S1295 and D3S1029 were the most frequent markers in precancerous lesions. LOH of D3S1295 had significant correlation with negative expression of FHIT. Positive expression of hMLH1 and hMSH2 protein was detected in breast carcinomas in scattered distribution and their positive rate was 45% and 40% , respectively. In precancerous lesions, hMLH1 and hMSH2 protein showed diffuse expression and their positive rate was 61. 54% and 76. 92% , respectively, significantly lower than that in the control tissues.CONCLUSION:Defective expression of MMR genes is closely associated with the development of breast cancer. Genomic instability might play a role in the early stage during multi-step mammary carcinogenesis. MSI indicates poor histological differentiation in breast carcinoma. D3S1766 and D2S2739 might be the sensitive sites to detect MSI in breast carcinoma and precancerous lesions. The smallest common LOH deletion regions seem likely to be situated between 3p14 and 3p25, indicating the existence of breast tumor related genes in those regions and some of them might affect tumor development.

Loss of heterozygosity on chromosome 3p, 7q, and 17p is associated with lymph node involvement and poor prognosis in human breast cancer

Loss of Heterozygosity on Chromosome 3p in Breast Cancer and Precancerous Lesion

Loss of heterozygosity at chromosome 3P14-24 in patients with breast cancer

Loss of Heterozygosity on Chromosome 3p in Thyroid Tumors

Germline RECQL Gene Mutations in Chinese Patients with Breast Cancer

Incidence and Risk Factors of Lymph Node Metastasis in Breast Cancer Patients Without Preoperative Chemoradiotherapy and Neoadjuvant Therapy: Analysis of SEER Data.

The Association of Frequent Allelic Loss on 17p13.1 with Early Metastastic Recurrence of Hepatocellular Carcinoma after Liver Transplantation

Loss of heterozygosity on chromosome 17p13.3 in ovarian cancer and cervical cancer

The Roles of Loss of Heterozygosity at 8p22 in the Molecular Classification of Patients with Hepatocellular Carcinoma, with Special Reference to Survival after Surgical Operation

Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers

Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma

Relationship Between the Loss of Heterozygosity of Nm23-H1 Gene and the Metastasis in Lung Cancer

[Loss of Heterozygosity Analysis to Define Putative Region Involved in Tumor Differentiation and Metastases in Sporadic Colorectal Cancer Patients].

Preliminary study on the loss of heterozygosity at 17p13 in gastric and colorectal cancers.

Microsatellite Instability and Allele-Specific Chromosome 3p Deletion in Breast Cancer and Precancerous Lesions

Loss of Heterozygosity at D8S298 is a Predictor for Long-term Survival of Patients with Tumor-Node-Metastasis Stage I of Hepatocellular Carcinoma

Loss of Heterozygosity on Chromosome 10Q22-10Q23 and 22q 11.2- 22q 12.1 and P53 Gene in Primary Hepatocellular Carcinoma

[Loss of Heterozygosity at Chromosome 3p14, 25 in Serum DNA from Ovarian Cancer Patients].

From Risk to Survival: Chromosome 3p Aberrations in Renal Cell Carcinoma

Loss of Heterozygosity Analysis on Chromosome 8p in Hepatocellular Carcinoma Based on Laser Capture Microdissection

Loss, mutation and deregulation of L3MBTL4 in breast cancers